Bone Biologics Corporation
BBLG
$1.16
-$0.05-4.13%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.12% | -8.59% | -8.26% | -21.96% | -17.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.32% | 6.08% | -13.35% | -39.39% | -55.25% |
| Operating Income | 23.32% | -6.08% | 13.35% | 39.39% | 55.25% |
| Income Before Tax | 24.40% | 4.70% | 17.56% | 30.16% | 54.04% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.40% | 4.70% | 17.56% | 30.16% | 54.04% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.40% | 4.70% | 17.56% | 30.16% | 54.04% |
| EBIT | 23.32% | -6.08% | 13.35% | 39.39% | 55.25% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 86.58% | 84.26% | 65.66% | 73.17% | 92.78% |
| Normalized Basic EPS | 78.73% | 75.63% | 81.92% | 84.60% | 95.38% |
| EPS Diluted | 86.58% | 84.26% | 65.66% | 73.17% | 92.78% |
| Normalized Diluted EPS | 78.73% | 75.63% | 81.92% | 84.60% | 95.38% |
| Average Basic Shares Outstanding | 363.59% | 389.28% | 301.52% | 363.71% | 382.20% |
| Average Diluted Shares Outstanding | 363.59% | 389.28% | 301.52% | 363.71% | 382.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |